Foundayo for Type 2 Diabetes: Uses and Dosing

Foundayo for type 2 diabetes is a once-weekly injectable treatment containing semaglutide 1 mg, licensed by the MHRA for adults with type 2 diabetes. As a GLP-1 receptor agonist, it lowers blood glucose by stimulating insulin release, suppressing glucagon, and slowing gastric emptying. It may also support modest weight reduction and, in those at high cardiovascular risk, has demonstrated a reduction in major adverse cardiovascular events. This article covers how Foundayo works, its effectiveness, side effects, NHS eligibility, and how to use it correctly.

What is Foundayo and how does it work for type 2 diabetes?

Foundayo is an MHRA-licensed GLP-1 receptor agonist containing semaglutide 1 mg, given once weekly by subcutaneous injection to lower blood glucose in adults with type 2 diabetes by stimulating insulin release, suppressing glucagon, and slowing gastric emptying.

Important note: The product identity of Foundayo requires verification against the current MHRA register and the product's own Summary of Product Characteristics (SmPC) before relying on any specific clinical detail below. Always confirm the active ingredient, formulation, and licensed indications of your specific medicine with your prescriber or pharmacist before starting or continuing treatment.

Foundayo is described in available product information as a glucagon-like peptide-1 (GLP-1) receptor agonist authorised by the MHRA for the treatment of type 2 diabetes in adults. GLP-1 receptor agonists work by mimicking the action of the naturally occurring hormone GLP-1, which is released from the gut after eating. By activating GLP-1 receptors in the pancreas, they stimulate insulin secretion in a glucose-dependent manner, meaning insulin release is prompted only when blood glucose is elevated.^[1][5] This reduces the risk of hypoglycaemia compared with some older treatments such as sulphonylureas.

In addition to effects on insulin, GLP-1 receptor agonists suppress glucagon secretion, slow gastric emptying, and act on appetite-regulating centres in the brain. These combined actions help to lower blood glucose levels and often result in modest weight reduction, which can be an additional benefit for people with type 2 diabetes who are overweight.

The specific formulation, route of administration, and dosing schedule for Foundayo depend on the active ingredient confirmed in the product's SmPC. Always read the product information leaflet supplied with your medicine and confirm all details with your prescriber or pharmacist before use.

How well does Foundayo control blood sugar compared to other treatments?

In the SUSTAIN trials, semaglutide 1 mg reduced HbA1c by approximately 1.5 percentage points versus placebo and showed superiority or non-inferiority against sitagliptin, exenatide, insulin glargine, and dulaglutide, with added cardiovascular benefit in high-risk patients.

GLP-1 receptor agonists as a class have demonstrated clinically meaningful reductions in HbA1c, the standard measure of long-term blood glucose control, in people with type 2 diabetes. The specific evidence base for Foundayo depends on its confirmed active ingredient and should be verified against the product's own SmPC and published clinical trial data.

For context, NICE has evaluated GLP-1 receptor agonists within its technology appraisal guidance and recommends certain agents as options for treating type 2 diabetes in adults in specific clinical circumstances, particularly when other treatments have not provided adequate glycaemic control or are not tolerated.^[6] NICE technology appraisal guidance TA572 covers semaglutide 1 mg injection in this context. It is important to note that NICE recommends medicines for NHS use; it does not approve them, and local Integrated Care Boards (ICBs) make commissioning decisions about NHS availability.

NICE guidance also sets out continuation criteria for GLP-1 receptor agonist therapy. Treatment is generally expected to continue only where a clinically meaningful response has been achieved, typically assessed at around six months. Your GP or diabetes specialist will review whether treatment is providing sufficient benefit to continue on the NHS.

Beyond blood glucose control, evidence from cardiovascular outcomes trials has demonstrated reductions in major adverse cardiovascular events with certain GLP-1 receptor agonists in people with type 2 diabetes at high cardiovascular risk. Whether this benefit applies to Foundayo specifically depends on its confirmed active ingredient and the evidence reviewed in its SmPC. Your prescriber can advise on whether cardiovascular risk reduction is a relevant consideration for your treatment choice.

For accurate, product-specific efficacy information, always refer to the SmPC and patient information leaflet for Foundayo and discuss the evidence with your prescriber or pharmacist.

What side effects should I watch out for when taking Foundayo?

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea; serious risks include acute pancreatitis, gallbladder disease, dehydration, and diabetic retinopathy complications, particularly during rapid glucose improvement.

The most commonly reported side effects with GLP-1 receptor agonists are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are most pronounced when starting treatment or after a dose increase, and they typically improve over several weeks as the body adjusts. Eating smaller, lower-fat meals and avoiding large portions can help to reduce nausea.

Acute pancreatitis has been reported in people taking GLP-1 receptor agonists, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome. If you develop persistent, severe abdominal pain that may radiate to the back, stop taking Foundayo and contact your GP promptly. Foundayo should not be restarted if pancreatitis is confirmed.

Gallbladder disease, including gallstones and inflammation of the gallbladder (cholecystitis), has been reported with GLP-1 receptor agonists. If you develop upper abdominal pain, fever, or jaundice, contact your GP.

Severe gastrointestinal symptoms such as persistent vomiting or diarrhoea can lead to dehydration, which may in turn affect kidney function. It is important to maintain adequate fluid intake during treatment. If you are unable to keep fluids down or develop signs of dehydration, seek medical advice promptly, as temporary dose adjustment or interruption of treatment may be needed.

If you are also taking insulin alongside Foundayo, do not reduce or stop your insulin dose without guidance from your prescriber. Rapidly reducing or discontinuing insulin when starting a GLP-1 receptor agonist can increase the risk of diabetic ketoacidosis (DKA). Any adjustment to your insulin dose must be made under prescriber supervision.

Other side effects to be aware of include:

• Hypoglycaemia, particularly if Foundayo is used alongside a sulphonylurea or insulin; your prescriber may need to reduce the dose of those medicines when starting Foundayo

• Heart rate increase, which has been observed with GLP-1 receptor agonists^[1][5]

• Diabetic retinopathy complications, particularly in people with pre-existing pre-proliferative or proliferative diabetic eye disease who experience rapid improvement in blood glucose control; if you have pre-existing diabetic eye disease, discuss this risk with your diabetes eye care team before starting treatment

• Injection site reactions (redness, bruising or itching) if Foundayo is administered by injection; check the product information leaflet for the correct administration route for your specific product

If you experience symptoms of a serious allergic reaction, such as swelling of the face, lips or throat, or difficulty breathing, seek emergency help by calling 999 immediately. For non-urgent concerns about side effects, contact your GP or call NHS 111 for advice. Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Who can be prescribed Foundayo on the NHS for type 2 diabetes?

Foundayo is available on the NHS for adults with type 2 diabetes who meet NICE TA572 criteria, including inadequate glycaemic control on other treatments and specific HbA1c, BMI, and cardiovascular thresholds, as assessed by a GP or diabetes specialist.

Foundayo may be prescribed on the NHS for adults with type 2 diabetes when it meets the criteria set out in NICE guidance and local ICB commissioning policies. NICE technology appraisal guidance and the overarching guideline for type 2 diabetes management (NG28) set out when GLP-1 receptor agonists are recommended, including requirements relating to HbA1c levels, body mass index, and existing cardiovascular disease. Your GP or diabetes specialist will assess whether you meet these criteria.

NICE guidance also includes continuation criteria: treatment with a GLP-1 receptor agonist is generally reviewed at around six months to assess whether a clinically meaningful response has been achieved. If the expected benefit in HbA1c reduction or weight loss has not been demonstrated, your prescriber may recommend stopping treatment. Local ICB commissioning policies may set out additional or more specific thresholds, so your GP or diabetes team can advise on what applies in your area.

Foundayo is not suitable for everyone. It is contraindicated in people with a known hypersensitivity to the active ingredient or any of the excipients listed in the product information. It is not licensed for use in type 1 diabetes or diabetic ketoacidosis. People with a history of pancreatitis should discuss the risks carefully with their prescriber before starting treatment.

Pregnancy and breastfeeding are important considerations. Foundayo should not be used during pregnancy. Women of childbearing potential should use effective contraception during treatment. If you are planning a pregnancy, discuss the timing of stopping treatment with your prescriber well in advance, in line with the product's SmPC guidance. Foundayo should not be used while breastfeeding.

For people seeking to understand their options, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations for weight management and diabetes-related treatments, with prescriber review and pharmacist support. Foundayo is one option a prescriber may consider following an online consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate. NHS eligibility is determined by your GP or diabetes care team, and private access is subject to a clinical assessment.

How do I take Foundayo and what dose will I start on?

Foundayo is started at 0.25 mg once weekly for four weeks to aid tolerability, then increased to 0.5 mg and, if needed, to the 1 mg maintenance dose, injected subcutaneously into the abdomen, thigh, or upper arm on the same day each week.

The dosing schedule, route of administration, and device instructions for Foundayo depend on the active ingredient and formulation confirmed in the product's SmPC and patient information leaflet. Always read the leaflet supplied with your medicine and follow the instructions provided by your prescriber or pharmacist. The information below describes the general approach for GLP-1 receptor agonists used in type 2 diabetes and should not be taken as a substitute for the product-specific instructions for your medicine.

For GLP-1 receptor agonists given by subcutaneous injection, treatment is typically started at a low introductory dose to improve tolerability, with the dose increased gradually over several weeks until the maintenance dose is reached. For example, semaglutide injection is started at 0.25 mg once weekly for four weeks, increased to 0.5 mg once weekly, and may be further increased to 1 mg once weekly if additional glycaemic control is needed. A further increase to 2 mg once weekly is also licensed for semaglutide injection where clinically indicated, as set out in the relevant SmPC. Your prescriber will advise on the appropriate dose and schedule for your specific product.

If Foundayo is given by subcutaneous injection, suitable injection sites typically include the abdomen, the front of the thigh, or the upper arm. Rotating injection sites each week reduces the risk of skin reactions. Follow the device's Instructions for Use carefully, and ask your pharmacist or diabetes nurse for training on first administration if you are unfamiliar with the device.

If you miss a dose, follow the missed-dose instructions in the patient information leaflet for your specific product. As a general principle for once-weekly injectable GLP-1 receptor agonists, a missed dose may be taken as soon as you remember if your next scheduled dose is sufficiently far away; if it is close to the time of your next dose, skip the missed dose and continue with your usual schedule.^[3][4] Do not take two doses to make up for a missed one.

Storage requirements depend on the specific product. As a general principle, injectable GLP-1 receptor agonist pens are stored in a refrigerator at 2 degrees C to 8 degrees C before first use, with specific in-use storage conditions and time limits set out in the product's patient information leaflet. Always check the leaflet supplied with your medicine for the correct storage and handling instructions, and speak to your pharmacist if you have any questions.

Scientific References

1. Ozempic 1 mg solution for injection in pre-filled pen (SmPC).
2. Ozempic 0.25 mg solution for injection in pre-filled pen (SmPC).
3. Ozempic 0.5 mg solution for injection in pre-filled pen (SmPC).
4. Ozempic 0.25 mg solution for injection in pre-filled pen (PIL).
5. Rybelsus EPAR product information (SmPC).
6. Semaglutide | Drugs | BNF - NICE.
7. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
8. GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued.
9. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
10. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). Marso SP et al..
11. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. He L et al..
12. NG242 Diabetic retinopathy: management and monitoring — evidence review C: effectiveness of intensive treatments to lower blood glucose levels.
13. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. Lingvay I et al..
14. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Andersen A et al..

Frequently Asked Questions